Company intelligence / Profile preview

Stapgen

Boston/Burlington area, Massachusetts, United Statesstapgen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Stapgen has developed a patented diagnostic test, the STAP-Test, which measures intestinal alkaline phosphatase levels in stool to predict the risk of developing Type 2 Diabetes before clinical onset. The technology is positioned as a preventive tool, aiming to identify at-risk individuals during the incipient phase of disease progression. Clinical validation and broad commercialization are ongoing; no large-scale published clinical trial results yet available.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Device (diagnostic test kit)Diagnostic assay (biomarker-based)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

SGt2d

Pre-clinical

Indications: Type 2 diabetes mellitus

Beyond the preview

Go deeper on Stapgen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stapgen.

Explore the full profile